also on other fortune lists

company facts

f500 stats

Fortune 500

Martin Leissl — Bloomberg via Getty Images




Merck brought in $39.8 billion in 2016 global sales. The U.S. drug giant’s wide-ranging portfolio was crucial to that haul but the company’s next-generation cancer immunotherapy treatment, Keytruda, is what really set it apart last year. The therapy bested rival Bristol-Myers Squibb’s competing Opdivo in the critical lung cancer space, according to clinical trial data, making it (and Merck) one of the most formidable players in the latest strike on cancer.

Looking for leads, investment insights, or competitive intelligence?


Kenneth C. Frazier

CEO Title

Chairman, President & Chief Executive Officer


Health Care



HQ Location

Kenilworth, NJ

Years on Fortune 500 List




Profile provided by S&P Global.
Merck is also featured in these fortune lists
Key Financials (Last Fiscal Year)
$ millions% change
Revenues ($M)$39,8070.8%
Profits ($M)$3,920.0-11.8%
Assets ($M)$95,377
Total Stockholder Equity ($M)$40,088
Market Value — as of March 31, 2017 ($M)$174,454
Profit Ratios
Profit as % of Revenues9.8%
Profits as % of Assets4.1%
Profits as % of Stockholder Equity9.8%
Earnings Per Share (Last Fiscal Year)
Earnings Per Share ($)1.41
EPS % Change (from 2015)-9.6%
EPS % Change (5 year annual rate)-6.9%
EPS % Change (10 year annual rate)-3.6%
Total Return
Total Return to Investors (2016)15.1%
Total Return to Investors (5 year, annualized)13.2%
Total Return to Investors (10 year, annualized)7.0%
()0.00 0.00 (0)
  • Previous Close:
  • Market Cap: NaNB
  • Next Earnings Date:
  • High:
  • Low:
  • 52 Week High:
  • 52 Week Low:
  • 52 Week Change %: 0.00
  • P/E Ratio: n/a
  • EPS:
  • Dividend Yield: n/a

News about Merck

2017 Saw the Most New Drugs Approved in Over 20 Years

The FDA approved 46 novel drugs in 2017 versus 22 in 2016.

Read More →
Alzheimer's Cases Are Expected to Double By 2060 and We're Not Ready for It

There still aren't any truly effective drugs for Alzheimer's or dementia.

Read More →
Could a New Immunotherapy Medical Approach Break the Alzheimer's Drug Curse?

AbbVie and Alector hope to apply immunotherapy to dementia and Alzheimer's.

Read More →
Tanium CEO's Refreshingly Honest Take on the State of Internet Security

This is your Cyber Saturday edition of Fortune's tech newsletter for October 7, 2017.

Read More →